Celldex Therapeutics Inc. (CLDX): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celldex Therapeutics ( CLDX) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day down 0.5%. By the end of trading, Celldex Therapeutics rose $1.41 (7.4%) to $20.36 on average volume. Throughout the day, 2,699,027 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 1,871,100 shares. The stock ranged in a price between $19.28-$20.50 after having opened the day at $19.54 as compared to the previous trading day's close of $18.95. Other companies within the Health Care sector that increased today were: Galectin Therapeutics ( GALT), up 21.7%, Savient Pharmaceuticals ( SVNT), up 18.6%, GW Pharmaceuticals PLC ADR ( GWPH), up 14.8% and Response Genetics ( RGDX), up 14.5%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $1.5 billion and is part of the drugs industry. Shares are up 182.4% year to date as of the close of trading on Friday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

On the negative front, Biota Pharmaceuticals ( BOTA), down 62.7%, Vical Incorporated ( VICL), down 57.3%, Mast Therapeutics ( MSTX), down 41.4% and Inovio Pharmaceuticals ( INO), down 21.4% , were all laggards within the health care sector with Regeneron Pharmaceuticals ( REGN) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%